Abstract | PURPOSE: PATIENTS AND METHODS: Forty patients with low-grade lymphocytic lymphomas including diffuse small lymphocytic, follicular small-cleaved, and follicular mixed histologies were enrolled onto the study. Conventional therapies had failed in all patients, and six patients had lymph node biopsies showing evidence of histologic evolution to a higher-grade lymphoma. A total of 107 courses of 2-CdA were administered. There were 27 males and 13 females. The median age was 59 years (range, 37 to 80 years). Patients had received a median of three prior therapies (range, one to six therapies). RESULTS: An overall response rate of 43% was achieved, with eight patients experiencing complete responses (CRs) and nine patients experiencing partial responses (PRs). The duration of responses ranged from 1 to greater than 33 months without maintenance therapy (median duration of response, 5 months). Histology and prior therapy history did not seem to correlate with responses. Significant toxicity was limited to bone marrow suppression; 18% of patients developed neutropenia, and 30% developed thrombocytopenia. CONCLUSIONS: This phase II trial demonstrates that 2-CdA is an effective antilymphocyte, antineoplastic agent with significant activity as a single agent in patients with recurrent or refractory low-grade lymphocytic lymphoma. Responses were achieved with an acceptable toxicity profile. Further trials of this agent in previously untreated patients and in combination regimens are indicated and will be developed.
|
Authors | A C Kay, A Saven, C J Carrera, D A Carson, D Thurston, E Beutler, L D Piro |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 10
Issue 3
Pg. 371-7
(Mar 1992)
ISSN: 0732-183X [Print] United States |
PMID | 1346801
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antineoplastic Agents
- Deoxyadenosines
- 2-Chloroadenosine
- Cladribine
|
Topics |
- 2-Chloroadenosine
(adverse effects, analogs & derivatives, therapeutic use)
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Bacterial Infections
(etiology)
- Bone Marrow Diseases
(chemically induced)
- Cladribine
- Deoxyadenosines
(adverse effects, therapeutic use)
- Drug Evaluation
- Female
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell
(drug therapy)
- Lymphoma, Follicular
(drug therapy)
- Lymphoma, Non-Hodgkin
(drug therapy)
- Male
- Middle Aged
- Remission Induction
- Treatment Outcome
|